Artgen Biotech PJSC Statistics
Total Valuation
Artgen Biotech PJSC has a market cap or net worth of RUB 4.29 billion. The enterprise value is 4.94 billion.
Market Cap | 4.29B |
Enterprise Value | 4.94B |
Important Dates
The next estimated earnings date is Thursday, February 13, 2025.
Earnings Date | Feb 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Artgen Biotech PJSC has 71.99 million shares outstanding. The number of shares has decreased by -0.41% in one year.
Current Share Class | n/a |
Shares Outstanding | 71.99M |
Shares Change (YoY) | -0.41% |
Shares Change (QoQ) | -33.44% |
Owned by Insiders (%) | 46.62% |
Owned by Institutions (%) | 0.14% |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 20.02.
PE Ratio | 20.02 |
Forward PE | n/a |
PS Ratio | 2.95 |
PB Ratio | 10.17 |
P/TBV Ratio | 16.10 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.59, with an EV/FCF ratio of 16.57.
EV / Earnings | 22.43 |
EV / Sales | 3.31 |
EV / EBITDA | 12.59 |
EV / EBIT | 15.16 |
EV / FCF | 16.57 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.83.
Current Ratio | 1.88 |
Quick Ratio | 1.01 |
Debt / Equity | 0.83 |
Debt / EBITDA | 1.93 |
Debt / FCF | 2.65 |
Interest Coverage | 6.51 |
Financial Efficiency
Return on equity (ROE) is 29.67% and return on invested capital (ROIC) is 12.72%.
Return on Equity (ROE) | 29.67% |
Return on Assets (ROA) | 8.81% |
Return on Capital (ROIC) | 12.72% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.61 |
Inventory Turnover | 1.81 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +55.78% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +55.78% |
50-Day Moving Average | 66.85 |
200-Day Moving Average | 91.44 |
Relative Strength Index (RSI) | 40.78 |
Average Volume (20 Days) | 234,009 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Artgen Biotech PJSC had revenue of RUB 1.49 billion and earned 220.07 million in profits. Earnings per share was 2.97.
Revenue | 1.49B |
Gross Profit | 1.07B |
Operating Income | 342.72M |
Pretax Income | 269.26M |
Net Income | 220.07M |
EBITDA | 383.30M |
EBIT | 342.72M |
Earnings Per Share (EPS) | 2.97 |
Balance Sheet
The company has 394.93 million in cash and 789.60 million in debt, giving a net cash position of -394.67 million or -5.48 per share.
Cash & Cash Equivalents | 394.93M |
Total Debt | 789.60M |
Net Cash | -394.67M |
Net Cash Per Share | -5.48 |
Equity (Book Value) | 953.87M |
Book Value Per Share | 5.85 |
Working Capital | 475.69M |
Cash Flow
In the last 12 months, operating cash flow was 495.43 million and capital expenditures -197.47 million, giving a free cash flow of 297.96 million.
Operating Cash Flow | 495.43M |
Capital Expenditures | -197.47M |
Free Cash Flow | 297.96M |
FCF Per Share | 4.14 |
Margins
Gross margin is 71.57%, with operating and profit margins of 22.96% and 14.74%.
Gross Margin | 71.57% |
Operating Margin | 22.96% |
Pretax Margin | 18.04% |
Profit Margin | 14.74% |
EBITDA Margin | 25.68% |
EBIT Margin | 22.96% |
FCF Margin | 19.96% |
Dividends & Yields
Artgen Biotech PJSC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.41% |
Shareholder Yield | 0.41% |
Earnings Yield | 4.99% |
FCF Yield | 6.95% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Artgen Biotech PJSC has an Altman Z-Score of 1.45. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.45 |
Piotroski F-Score | n/a |